Retail investors buy Novo dip after disappointing weight-loss drug data

By Bhanvi Satija (Reuters) – U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker’s weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research. Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo’s experimental drug,…

Read More